6Tanaka M.Pharmacologiocal and clinical profile of the free radical scavenger edaravone as a neuroprotective agent[J].Nippon Yakurigaku Zasshi,2002,119(5):301 -308.
8Eiichi O.Effect of a novel free radical scavenger edaravone(MCI186) on acute brain infarction[J].Cerebrovasc Dis,2003,15(3):222 -229.
9Shimon A,Tstsushi K.Expression 'of anti-apoptotic and neuroproreceive effects of edaravone following transient focal ischemia in rats[J].Eur J Phannaco],2005,516(2):125-130.
10Nilasena DS,Kresowik TF,Wiblin RT,et al.Assessing patterns of tPA use in acute stroke[J].Stroke,2002,33:354.
4Pazhayattil GS, Shirali AC. Drug-induced impairment of renalfunction[ J]. Int J Nephrol Renovasc Dis, 2014, 7 : 457-468.
5Jang SM, Cerulli J,Grabe DW, et al. NSAID-avoidance educa-tion in community pharmacies for patients at high risk for acutekidney injury, upstate New York, 2011 [ J]. Prev Chronic Dis,2014, 11: E220.
6Abe M, Kaizu K, Matsumoto K. A case report of acute renal fail-ure and fulminant hepatitis associated with edaravone administra-tion in a cerebral infarction patient[ J]. Ther Apher Dial,2007,11(3) : 235-240.
7Ronco C, Levin A, Wamock DG, et al. Improving outcomes fromacute kidney injury(AKI) : Report on an initiative[ J]. Int J ArtifOrgans, 2007, 30(5) : 373-376.
8Hishida A. Clinical analysis of 207 patients who developed renaldisorders during or after treatment with edaravone reported duringpost-marketing surveillance [ J ]. Clin Exp Nephrol,2007,11(4): 292-296.
10Hishida A. Determinants for the prognosis of acute renal disordersthat developed during or after treatment with edaravone[ J]. ClinExp Nephrol, 2009,13(2) : 118-122.
